Skip to main content
Top
Published in: Journal of Translational Medicine 1/2021

Open Access 01-12-2021 | Review

Why scientists, academic institutions, and investors fail in bringing more products to the bedside: the Active Compass model for overcoming the innovation paradox

Author: Yaron Ilan

Published in: Journal of Translational Medicine | Issue 1/2021

Login to get access

Abstract

The vast majority of good science and excellent ideas do not translate into products. Many good products that have the potential to assist in diagnosis and therapy do not mature into everyday care. This often becomes a source of frustration for innovators, academic institutions, companies both small and large, and investors. The “innovation paradox” , wherein excellent ideas and good science fail to reach the bedside, is a major challenge. This study presents the Active Compass model as a way to overcome this obstacle. The model is designed to assist projects at early stages by redirecting and reshaping them in a way that increases their chances of reaching the markets. The model is based on the use of next-generation translational research and on creating differentiators at the early stages of development. The proposed model’s implementation by innovators, scientists, technology transfer offices, academic institutions, analysts, and investors can help move forward high-potential projects to improve the quality of life and alleviate the burdens of disease.
Literature
1.
3.
go back to reference Cunningham S. 3 tips for pharma startup success. Drug Discov Today. 2020;25:1291–2.CrossRef Cunningham S. 3 tips for pharma startup success. Drug Discov Today. 2020;25:1291–2.CrossRef
4.
go back to reference Huggett B. In conversation with four startup CEOs. Nat Biotechnol. 2020;38:533–6.CrossRef Huggett B. In conversation with four startup CEOs. Nat Biotechnol. 2020;38:533–6.CrossRef
5.
go back to reference Ruffell D. The six steps to a successful start-up: an interview with Kai Simons. FEBS Lett. 2019;593:655–7.CrossRef Ruffell D. The six steps to a successful start-up: an interview with Kai Simons. FEBS Lett. 2019;593:655–7.CrossRef
6.
go back to reference Wlodarek J. Top tips for a successful practice start-up. J Mass Dent Soc. 2014;63:10.PubMed Wlodarek J. Top tips for a successful practice start-up. J Mass Dent Soc. 2014;63:10.PubMed
7.
go back to reference Strovel J, Sittampalam S, Coussens NP, et al. Early drug discovery and development guidelines: for academic researchers, collaborators, and start-up companies. In: Markossian S, Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr, Weidner JR, Wildey MJ, Xia M, Xu X, editors., et al., Assay Guidance Manual. Bethesda: Springer; 2004. Strovel J, Sittampalam S, Coussens NP, et al. Early drug discovery and development guidelines: for academic researchers, collaborators, and start-up companies. In: Markossian S, Sittampalam GS, Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J, Caaveiro JMM, Chung TDY, Coussens NP, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Hoare SRJ, Inglese J, Iversen PW, Kahl SD, Kales SC, Kirshner S, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Saradjian P, Trask OJ Jr, Weidner JR, Wildey MJ, Xia M, Xu X, editors., et al., Assay Guidance Manual. Bethesda: Springer; 2004.
8.
go back to reference Rubio DM, Schoenbaum EE, Lee LS, et al. Defining translational research: implications for training. Acad Med. 2010;85:470–5.CrossRef Rubio DM, Schoenbaum EE, Lee LS, et al. Defining translational research: implications for training. Acad Med. 2010;85:470–5.CrossRef
9.
go back to reference Nakao K. Translational science: Newly emerging science in biology and medicine—lessons from translational research on the natriuretic peptide family and leptin. Proc Jpn Acad Ser B Phys Biol Sci. 2019;95:538–67.CrossRef Nakao K. Translational science: Newly emerging science in biology and medicine—lessons from translational research on the natriuretic peptide family and leptin. Proc Jpn Acad Ser B Phys Biol Sci. 2019;95:538–67.CrossRef
10.
go back to reference Stefely JA, Theisen E, Hanewall C, et al. A physician-scientist preceptorship in clinical and translational research enhances training and mentorship. BMC Med Educ. 2019;19:89.CrossRef Stefely JA, Theisen E, Hanewall C, et al. A physician-scientist preceptorship in clinical and translational research enhances training and mentorship. BMC Med Educ. 2019;19:89.CrossRef
11.
go back to reference Kluijtmans M, de Haan E, Akkerman S, et al. Professional identity in clinician-scientists: brokers between care and science. Med Educ. 2017;51:645–55.CrossRef Kluijtmans M, de Haan E, Akkerman S, et al. Professional identity in clinician-scientists: brokers between care and science. Med Educ. 2017;51:645–55.CrossRef
12.
go back to reference Jinawath N, Bunbanjerdsuk S, Chayanupatkul M, et al. Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research. J Transl Med. 2016;14:324.CrossRef Jinawath N, Bunbanjerdsuk S, Chayanupatkul M, et al. Bridging the gap between clinicians and systems biologists: from network biology to translational biomedical research. J Transl Med. 2016;14:324.CrossRef
13.
go back to reference Shah S, Villemain OL. Saving the endangered physician-scientists: reintroducing them to an environment of administrative support. J Investig Med. 2020;68:1206–7.CrossRef Shah S, Villemain OL. Saving the endangered physician-scientists: reintroducing them to an environment of administrative support. J Investig Med. 2020;68:1206–7.CrossRef
14.
go back to reference Perumalswami CR, Takenoshita S, Tanabe A, et al. Workplace resources, mentorship, and burnout in early career physician-scientists: a cross sectional study in Japan. BMC Med Educ. 2020;20:178.CrossRef Perumalswami CR, Takenoshita S, Tanabe A, et al. Workplace resources, mentorship, and burnout in early career physician-scientists: a cross sectional study in Japan. BMC Med Educ. 2020;20:178.CrossRef
15.
go back to reference Iness AN. Waiting to “make it” versus “making it happen”: empowering physician-scientists in training. J Clin Invest. 2019;129:5062–5.CrossRef Iness AN. Waiting to “make it” versus “making it happen”: empowering physician-scientists in training. J Clin Invest. 2019;129:5062–5.CrossRef
16.
go back to reference Strong MJ, Busing N, Goosney DL, et al. The rising challenge of training physician-scientists: recommendations from a canadian national consensus conference. Acad Med. 2018;93:172–8.CrossRef Strong MJ, Busing N, Goosney DL, et al. The rising challenge of training physician-scientists: recommendations from a canadian national consensus conference. Acad Med. 2018;93:172–8.CrossRef
17.
go back to reference Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48:417–33.CrossRef Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48:417–33.CrossRef
18.
go back to reference Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol. 2018;31:296–304.PubMedPubMedCentral Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol. 2018;31:296–304.PubMedPubMedCentral
19.
go back to reference Ilan Y. Overcoming compensatory mechanisms toward chronic drug administration to ensure long-term, sustainable beneficial effects. Mol Ther Methods Clin Dev. 2020;18:335–44.CrossRef Ilan Y. Overcoming compensatory mechanisms toward chronic drug administration to ensure long-term, sustainable beneficial effects. Mol Ther Methods Clin Dev. 2020;18:335–44.CrossRef
20.
go back to reference Loscher W, Potschka H, Sisodiya SM, et al. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606–38.CrossRef Loscher W, Potschka H, Sisodiya SM, et al. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72:606–38.CrossRef
21.
go back to reference Reus GZ, de Moura AB, Borba LA, et al. Strategies for treatment-resistant depression: lessons learned from animal models. Mol Neuropsychiatry. 2019;5:178–89.CrossRef Reus GZ, de Moura AB, Borba LA, et al. Strategies for treatment-resistant depression: lessons learned from animal models. Mol Neuropsychiatry. 2019;5:178–89.CrossRef
22.
go back to reference Kolben Y, Weksler-Zangen S, Ilan Y. Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: Implementing a personalized signature-based platform for chronotherapy. Obes Rev. 2020;7:27. Kolben Y, Weksler-Zangen S, Ilan Y. Adropin as a potential mediator of the metabolic system-autonomic nervous system-chronobiology axis: Implementing a personalized signature-based platform for chronotherapy. Obes Rev. 2020;7:27.
23.
go back to reference Potruch A, Khoury ST, Ilan Y. The role of chronobiology in drug-resistance epilepsy: the potential use of a variability and chronotherapy-based individualized platform for improving the response to anti-seizure drugs. Seizure. 2020;80:201–11.CrossRef Potruch A, Khoury ST, Ilan Y. The role of chronobiology in drug-resistance epilepsy: the potential use of a variability and chronotherapy-based individualized platform for improving the response to anti-seizure drugs. Seizure. 2020;80:201–11.CrossRef
24.
go back to reference Forkosh E, Kenig A, Ilan Y. Introducing variability in targeting the microtubules: review of current mechanisms and future directions in colchicine therapy. Pharmacol Res Perspect. 2020;8:e00616.CrossRef Forkosh E, Kenig A, Ilan Y. Introducing variability in targeting the microtubules: review of current mechanisms and future directions in colchicine therapy. Pharmacol Res Perspect. 2020;8:e00616.CrossRef
25.
go back to reference Gelman R, Bayatra A, Kessler A, et al. Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. Emerg Microbes Infect. 2020;9:1397–406.CrossRef Gelman R, Bayatra A, Kessler A, et al. Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents. Emerg Microbes Infect. 2020;9:1397–406.CrossRef
26.
go back to reference Ilan Y. Order through disorder: the characteristic variability of systems. Front Cell Dev Biol. 2020;8:186.CrossRef Ilan Y. Order through disorder: the characteristic variability of systems. Front Cell Dev Biol. 2020;8:186.CrossRef
27.
go back to reference Kenig A, Ilan Y. A personalized signature and chronotherapy-based platform for improving the efficacy of sepsis treatment. Front Physiol. 2019;10:1542.CrossRef Kenig A, Ilan Y. A personalized signature and chronotherapy-based platform for improving the efficacy of sepsis treatment. Front Physiol. 2019;10:1542.CrossRef
28.
go back to reference Khoury T, Ilan Y. Introducing patterns of variability for overcoming compensatory adaptation of the immune system to immunomodulatory agents: a novel method for improving clinical response to anti-TNF therapies. Front Immunol. 2019;10:2726.CrossRef Khoury T, Ilan Y. Introducing patterns of variability for overcoming compensatory adaptation of the immune system to immunomodulatory agents: a novel method for improving clinical response to anti-TNF therapies. Front Immunol. 2019;10:2726.CrossRef
29.
go back to reference El-Haj M, Kanovitch D, Ilan Y. Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies. Immunol Res. 2019;67:337–47.CrossRef El-Haj M, Kanovitch D, Ilan Y. Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies. Immunol Res. 2019;67:337–47.CrossRef
30.
go back to reference Kessler A, Weksler-Zangen S, Ilan Y. Role of the immune system and the circadian rhythm in the pathogenesis of chronic pancreatitis: establishing a personalized signature for improving the effect of immunotherapies for chronic pancreatitis. Pancreas. 2020;49:1024–32.CrossRef Kessler A, Weksler-Zangen S, Ilan Y. Role of the immune system and the circadian rhythm in the pathogenesis of chronic pancreatitis: establishing a personalized signature for improving the effect of immunotherapies for chronic pancreatitis. Pancreas. 2020;49:1024–32.CrossRef
Metadata
Title
Why scientists, academic institutions, and investors fail in bringing more products to the bedside: the Active Compass model for overcoming the innovation paradox
Author
Yaron Ilan
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2021
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-021-02726-4

Other articles of this Issue 1/2021

Journal of Translational Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine